Ous tumor growth. Cell 2010, 141(4):583-94. 35. O’Brien C, Pollett A, Gallinger
Ous tumor growth. Cell 2010, 141(4):583-94. 35. O’Brien C, Pollett A, Gallinger S, et al: A human colon buy BQ-123 cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445(7123):106-10. 36. Ricci-Vitiani L, Lombardi D, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445(7123):111-5. 37. Shmelkov S, Butler J, Hooper A, et al: CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008, 118(6):2111-20. 38. LaBarge M, Bissell M: Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest 2008, 118(6):2021-4. 39. Barker N, van Es J, Kuipers J, et al: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449(7165):1003-7. 40. Huang E, Hynes M, Zhang T, et al: Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009, 69(8):3382-9. 41. Dalerba P, Dylla S, Park I, et al: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007, 104(24):10158-63. 42. Pang R, Law W, Chu A, et al: A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010, 6(6):603-15. 43. Zhu L, Gibson P, Currle D, et al: Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 457(7229):603-7. 44. Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 2007, 67(3):1030-7. 45. Hermann P, Huber S, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1(3):313-23. 46. Prince M, Sivanandan R, Kaczorowski A, et al: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007, 104(3):973-8. 47. Chen Y, Chen Y, Hsu H, et al: Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009, 385(3):307-13. 48. Kong Y, Yoshida S, Saito Y, et al: CD34+CD38+CD19+ as well as CD34 +CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 2008, 22(6):1207-13.Liu et al. Journal of Translational Medicine 2011, 9:50 http://www.translational-medicine.com/content/9/1/Page 8 of49. Zhang S, Balch C, Chan M, et al: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008, 68(11):4311-20. 50. Baba T, Convery P, Matsumura N, et al: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28(2):209-18. 51. Rutella S, Bonanno G, Procoli A, et al: Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res 2009, 15(13):4299-311. 52. Yang Z, Ho D, Ng M, et al: Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13(2):153-66. 53. Suetsugu A, Nagaki M, Aoki H, et al: Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006, 351(4):820-4. 54. Terris B, Cavard PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/25645579 C, Perret C: EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010, 52(2):280-1.
